Opportunity Information: Apply for HRSA 16 189
Apply for HRSA 16 189
- The HHS-HRSA in the health sector is offering a public funding opportunity titled "Jurisdictional Approach to Curing Hepatitis C among HIV/HCV Coinfected People of Color – Jurisdictional Sites" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.928.
- This funding opportunity was created on May 16, 2016 and posted on May 16, 2016.
- Applicants must submit their applications by Jul 14, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Fiscal Year 2016 grant opportunity "Jurisdictional Approach to Curing Hepatitis C among HIV/HCV Coinfected People of Color - Jurisdictional Sites" (HRSA-16-189) is a Health Resources and Services Administration (HRSA) discretionary funding program offered as a cooperative agreement. Its central goal is to help selected Ryan White HIV/AIDS Program (RWHAP) jurisdictions build stronger, coordinated systems to find hepatitis C (HCV) in people living with HIV, connect them to care, and successfully treat and cure HCV, with a specific focus on people of color who are coinfected with HIV and HCV. Rather than funding isolated clinic-level projects, the announcement emphasizes jurisdiction-wide public health infrastructure improvements that can measurably increase screening, treatment initiation, and cure outcomes across an entire eligible city, county, or state system.
Eligibility is limited to current RWHAP grantees, specifically up to two Part A recipients and up to two Part B recipients, for a total of up to four awards. Applicants must demonstrate that HIV/HCV coinfection is a significant issue in their jurisdiction and that they have a proven ability to reach HIV-infected populations who are already living with HCV or are at heightened risk for acquiring it. The program is designed for jurisdictions that can realistically identify, engage, and treat populations most affected by inequities in HCV burden and access to care, including Black or African American communities, Latino/a communities, and American Indian or Alaska Native communities. It also explicitly highlights risk groups such as people who inject drugs (PWID) and notes that men who have sex with men (MSM) remain at risk for new (incident) HCV infection, reinforcing that jurisdictions should be prepared to address multiple transmission contexts.
A defining feature of this opportunity is the required close collaboration with a companion initiative: the Evaluation and Technical Assistance Center (ETAC) funded under HRSA-16-188. Because this is a cooperative agreement, recipients are not only funded but also expected to coordinate actively with HRSA-supported technical assistance and evaluation partners. In practical terms, jurisdictions are expected to use ETAC-developed tools, align their approaches with shared evaluation expectations, and participate in structured technical assistance designed to help them scale effective screening-to-cure systems. Recipients are also expected to coordinate with other training and clinical support resources, including the Regional AIDS Education and Training Centers (AETCs) in their area and the National AIDS Clinician Resource Center (NCRC), to strengthen provider readiness and clinical practice.
The first year is structured around rapid assessment and planning with clear deadlines. During the initial six months of Year 1, recipients must complete a needs assessment focused on gaps and barriers in existing HCV screening, care, and treatment for HIV/HCV coinfected people of color. This is not a superficial review; it requires a thorough examination of local HCV surveillance and epidemiologic patterns, along with any other relevant jurisdictional data sources, to understand who is affected, where the largest gaps occur, and how current systems perform along the care continuum. The assessment must also identify barriers at multiple levels, including structural barriers (such as service availability, referral pathways, and geographic access), financial barriers (including coverage and cost obstacles), and client-level barriers (such as stigma, competing needs, transportation, health literacy, or mistrust). In parallel, jurisdictions must review state and local laws and policies and scrutinize third-party payer policies related to coverage of HCV screening, clinical services, and medications, since insurance restrictions and prior authorization requirements have historically limited access to curative HCV therapy, especially for marginalized communities.
Within that same first six-month window, the program requires two additional assessments using ETAC tools. One is a patient knowledge assessment to understand what HIV/HCV coinfected clients know or misunderstand about HCV treatment, cure, and the steps involved in getting treated. The intention is to pinpoint education gaps that can be addressed through consumer-facing information and navigation supports. The second is a provider assessment to determine where clinicians and care teams may need training or technical assistance related to HCV screening recommendations, interpreting lab results, treatment eligibility, drug interactions, care coordination, and the practical steps required to initiate and monitor HCV therapy for people living with HIV. Completing all three assessments (surveillance and data review, patient knowledge assessment, and provider assessment) in the first six months is a core expectation and sets the foundation for the work that follows.
By the end of the ninth month of Year 1, each recipient must produce a project implementation plan that lays out how the jurisdiction will strengthen its public health infrastructure to expand HCV screening and treatment quickly and at scale. The announcement is explicit that this plan should describe a comprehensive, jurisdiction-wide, centrally coordinated program rather than scattered activities. At a minimum, the plan must include six components: first, a strategy to increase HCV screening among people of color living with HIV; second, provider training on HCV prevention, care, and treatment tailored to the needs of people of color living with HIV; third, patient education on HCV prevention, care, and treatment; fourth, clinical practice transformation to improve how clinical sites deliver HCV treatment for people of color living with HIV (which can include workflow redesign, new referral models, integration of services, and standardized protocols); fifth, concrete steps to increase access to HCV care and treatment, including access to medications; and sixth, enhanced medication adherence support for HCV therapy among HIV/HCV coinfected people of color, recognizing that adherence and follow-through are essential for cure and that many clients face barriers that require active support.
Years 2 and 3 focus on executing and refining the implementation plan to expand screening, linkage to care, treatment initiation, and successful completion of therapy. The expectation is that jurisdictions will move beyond planning into sustained operational improvements that change routine practice, strengthen interagency coordination, and create durable pathways from diagnosis to cure. By the end of the three-year project period, recipients are expected to have established effective, comprehensive jurisdiction-level HCV screening, care, and treatment systems and to demonstrate measurable improvements in HCV care outcomes among people coinfected with HIV. In other words, success is framed not just as increased activity (more tests or more trainings) but as improved outcomes across the HCV care continuum, including more people diagnosed, more people treated, and more people cured.
From an administrative standpoint, the funding opportunity is listed under CFDA 93.928 and was posted May 16, 2016, with an application closing date of July 14, 2016. The program anticipated four total awards. While an award ceiling is not specified in the provided source data, the structure and requirements make clear that HRSA intended to fund a small number of high-capacity jurisdictions that could serve as models for how RWHAP systems can partner with technical assistance, training networks, and public health data systems to close racial and ethnic gaps in HCV cure among people living with HIV.
FAQs: HRSA-16-189 (FY 2016) Jurisdictional Approach to Curing Hepatitis C among HIV/HCV Coinfected People of Color - Jurisdictional Sites
What is this funding opportunity (HRSA-16-189) trying to accomplish?
This cooperative agreement supports selected Ryan White HIV/AIDS Program (RWHAP) jurisdictions in building stronger, coordinated, jurisdiction-wide systems to identify hepatitis C (HCV) among people living with HIV, link them to care, and successfully treat and cure HCV. The focus is specifically on people of color who are coinfected with HIV and HCV, and on measurable improvements across the HCV screening-to-cure continuum at a city, county, or state level.
Who is the target population?
The program prioritizes people of color living with HIV who are coinfected with HCV, including Black or African American communities, Latino/a communities, and American Indian or Alaska Native communities. It also highlights key risk contexts that jurisdictions should be prepared to address, such as people who inject drugs (PWID) and men who have sex with men (MSM) who remain at risk for new (incident) HCV infection.
What type of award is HRSA offering under this opportunity?
HRSA is offering discretionary funding through a cooperative agreement. That means recipients are expected to actively coordinate with HRSA-supported partners for evaluation and technical assistance, rather than operating as fully independent grantees.
Is this opportunity intended to fund individual clinics or clinic-level projects?
No. The emphasis is on jurisdiction-wide public health infrastructure improvements that can increase HCV screening, treatment initiation, and cure outcomes across an entire eligible city, county, or state system, rather than funding isolated clinic-level efforts.
Who is eligible to apply?
Eligibility is limited to current RWHAP grantees. Specifically, up to two Part A recipients and up to two Part B recipients may be funded, for a total of up to four awards.
How many total awards were anticipated?
The opportunity anticipated up to four total awards.
What must applicants be able to demonstrate about their jurisdiction?
Applicants must demonstrate that HIV/HCV coinfection is a significant issue in their jurisdiction and that they have a proven ability to reach HIV-infected populations who are already living with HCV or are at heightened risk for acquiring HCV.
What is the relationship between HRSA-16-189 and HRSA-16-188?
Recipients under HRSA-16-189 are required to closely collaborate with a companion initiative, the Evaluation and Technical Assistance Center (ETAC), funded under HRSA-16-188. Jurisdictions are expected to use ETAC-developed tools, align with shared evaluation expectations, and participate in structured technical assistance to help scale effective screening-to-cure systems.
What other training and clinical support resources are recipients expected to coordinate with?
Recipients are expected to coordinate with the Regional AIDS Education and Training Centers (AETCs) in their area and the National AIDS Clinician Resource Center (NCRC) to strengthen provider readiness and clinical practice related to HCV screening, care, and treatment for people living with HIV.
What are the major Year 1 requirements?
Year 1 is front-loaded with rapid assessment and planning. In the first six months, recipients must complete three key assessments: (1) a needs assessment focused on gaps and barriers in existing HCV screening, care, and treatment for HIV/HCV coinfected people of color; (2) a patient knowledge assessment using ETAC tools; and (3) a provider assessment using ETAC tools. By the end of the ninth month, recipients must produce a project implementation plan that describes a comprehensive, jurisdiction-wide, centrally coordinated program.
What is required during the first six months of Year 1?
Within the first six months, recipients must complete a thorough needs assessment, including review of local HCV surveillance and epidemiologic patterns and other relevant jurisdictional data sources. They must also identify barriers at multiple levels (structural, financial, and client-level) and review state and local laws and policies, plus third-party payer policies related to HCV screening, services, and medications. In the same six-month window, recipients must also complete a patient knowledge assessment and a provider assessment using ETAC tools.
What kinds of barriers does the needs assessment need to cover?
The needs assessment must identify barriers at multiple levels, including structural barriers (such as service availability, referral pathways, and geographic access), financial barriers (including coverage and cost obstacles), and client-level barriers (such as stigma, competing needs, transportation, health literacy, or mistrust).
What data sources are recipients expected to examine in the needs assessment?
Recipients are expected to conduct a thorough examination of local HCV surveillance and epidemiologic patterns, along with any other relevant jurisdictional data sources, to understand who is affected, where gaps occur, and how current systems perform along the care continuum.
Why does the opportunity emphasize reviewing payer policies and laws?
Recipients are expected to scrutinize state and local laws and policies and third-party payer policies because coverage restrictions and prior authorization requirements have historically limited access to curative HCV therapy, particularly for marginalized communities. Understanding these constraints is part of building a workable jurisdiction-wide path from diagnosis to cure.
What is the patient knowledge assessment and what is it for?
The patient knowledge assessment (using ETAC tools) is intended to identify what HIV/HCV coinfected clients know or misunderstand about HCV treatment, cure, and the steps required to get treated. The goal is to pinpoint education gaps that can be addressed through consumer-facing information and navigation supports.
What is the provider assessment and what is it for?
The provider assessment (using ETAC tools) is designed to identify where clinicians and care teams need training or technical assistance, including HCV screening recommendations, interpreting lab results, treatment eligibility, drug interactions, care coordination, and the practical steps required to initiate and monitor HCV therapy for people living with HIV.
When is the implementation plan due, and what is it supposed to cover?
By the end of the ninth month of Year 1, each recipient must produce a project implementation plan describing how the jurisdiction will strengthen its public health infrastructure to expand HCV screening and treatment quickly and at scale. The plan should describe a comprehensive, jurisdiction-wide, centrally coordinated program rather than scattered activities.
What are the required components of the Year 1 implementation plan?
At a minimum, the implementation plan must include six components: (1) a strategy to increase HCV screening among people of color living with HIV; (2) provider training on HCV prevention, care, and treatment tailored to the needs of people of color living with HIV; (3) patient education on HCV prevention, care, and treatment; (4) clinical practice transformation to improve how clinical sites deliver HCV treatment for people of color living with HIV (including workflow redesign, referral models, integration, and standardized protocols); (5) steps to increase access to HCV care and treatment, including access to medications; and (6) enhanced medication adherence support for HCV therapy among HIV/HCV coinfected people of color.
What does "clinical practice transformation" mean in this program?
Clinical practice transformation refers to improving how clinical sites deliver HCV treatment for people of color living with HIV. The opportunity notes that this can include workflow redesign, new referral models, integration of services, and standardized protocols to make treatment initiation and completion more reliable at scale.
What happens in Years 2 and 3?
Years 2 and 3 focus on executing and refining the implementation plan to expand screening, linkage to care, treatment initiation, and successful completion of therapy. The expectation is sustained operational improvements that change routine practice, strengthen interagency coordination, and create durable pathways from diagnosis to cure.
How will success be judged by the end of the project period?
By the end of the three-year project period, recipients are expected to have established effective, comprehensive jurisdiction-level HCV screening, care, and treatment systems and to demonstrate measurable improvements in HCV care outcomes among people coinfected with HIV. Success is framed as improved outcomes across the care continuum (more people diagnosed, more people treated, and more people cured), not just increased activity like more tests or trainings.
What is the project period length described in the opportunity?
The described project period spans three years, with Year 1 focused on assessment and planning milestones and Years 2 and 3 focused on implementation and refinement.
What is the CFDA number for this opportunity?
The opportunity is listed under CFDA 93.928.
When was the opportunity posted and when did applications close?
The opportunity was posted on May 16, 2016, and the application closing date was July 14, 2016.
Is there an award ceiling listed in the provided information?
No. The provided information does not specify an award ceiling.
Why does HRSA describe this as a "jurisdictional" approach?
Because the work is meant to improve coordinated public health infrastructure and care pathways across an entire RWHAP jurisdiction (city, county, or state system). The intent is to build centralized, scalable systems that can measurably improve screening, treatment initiation, and cure outcomes across the whole jurisdiction.
Does the opportunity require alignment with a shared evaluation approach?
Yes. Because it is a cooperative agreement with required collaboration with ETAC, recipients are expected to align their approaches with shared evaluation expectations and use ETAC-developed tools.
Browse more opportunities from the same category: Health
Next opportunity: USAID and the PRIVATE SECTOR: PARTNERING FOR IMPACT
Previous opportunity: Inclusion of Mobile/e-Consents for Alzheimer's Disease Research (Admin Supp)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for HRSA 16 189
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (HRSA 16 189) also looked into and applied for these:
| Funding Opportunity |
|---|
| Reducing the Duration of Untreated Psychosis in the United States (R01) Apply for PAR 16 265 Funding Number: PAR 16 265 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Reducing the Duration of Untreated Psychosis in the United States (R34) Apply for PAR 16 264 Funding Number: PAR 16 264 Agency: HHS-NIH11 Category: Health Funding Amount: $225,000 |
| Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01) Apply for PAR 16 262 Funding Number: PAR 16 262 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Surveillance and Response to Avian and Pandemic Influenza by National Health Authorities Outside the United States Apply for CDC RFA IP16 1603 Funding Number: CDC RFA IP16 1603 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $400,000 |
| NHLBI Career Transition Award for Intramural Fellows (K22) Apply for PAR 16 267 Funding Number: PAR 16 267 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization Apply for CDC RFA IP16 1606 Funding Number: CDC RFA IP16 1606 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $2,000,000 |
| Introducing or Expanding the Use of Seasonal Influenza Vaccines in Public Health Programs Outside of the United States Apply for CDC RFA IP16 1604 Funding Number: CDC RFA IP16 1604 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $250,000 |
| NIAID Clinical Trial Implementation Grant (R01) Apply for PAR 16 269 Funding Number: PAR 16 269 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Partnerships for Structure-Based Design of Novel Immunogens for Vaccine Development (R01) Apply for RFA AI 16 047 Funding Number: RFA AI 16 047 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Limited Competition: Small Grant Program for NIAMS K08 and K23 Recipients (R03) Apply for PAR 16 268 Funding Number: PAR 16 268 Agency: HHS-NIH11 Category: Health Funding Amount: $50,000 |
| NIAID Clinical Trial Implementation Cooperative Agreement (U01) Apply for PAR 16 270 Funding Number: PAR 16 270 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| NIAID Clinical Trial Planning Grant (R34) Apply for PAR 16 272 Funding Number: PAR 16 272 Agency: HHS-NIH11 Category: Health Funding Amount: $150,000 |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) Apply for PAR 16 271 Funding Number: PAR 16 271 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Healthy Tomorrows Partnership for Children Program (HTPCP) Apply for HRSA 17 008 Funding Number: HRSA 17 008 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies (STD AAPPS) Apply for CDC RFA PS14 140204CONT17 Funding Number: CDC RFA PS14 140204CONT17 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| CDC’s National Undergraduate Student Program: A Public Health Workplace Experience to Increase Student Interest in Public Health Apply for CDC RFA MN11 110106CONT16 Funding Number: CDC RFA MN11 110106CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Fogarty Global Health Training Program (D43) Apply for RFA TW 16 002 Funding Number: RFA TW 16 002 Agency: HHS-NIH11 Category: Health Funding Amount: $1,100,000 |
| Surveillance, intervention, and referral to services activities for infants with microcephaly or other adverse outcomes linked with the Zika virus Apply for CDC RFA DD16 1605 Funding Number: CDC RFA DD16 1605 Agency: HHS-CDC-NCBDDD Category: Health Funding Amount: $360,000 |
| Developing New Clinical Decision Support to Disseminate and Implement Patient-Centered Outcomes Research Findings (R18) Apply for PA 16 282 Funding Number: PA 16 282 Agency: HHS-AHRQ Category: Health Funding Amount: $750,000 |
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Specialized Center Cooperative Agreements (U54) Apply for RFA OD 16 011 Funding Number: RFA OD 16 011 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "HRSA 16 189", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.